Your browser doesn't support javascript.
loading
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold, Linda Stein; Lebwohl, Mark G; Sugarman, Jeffrey L; Pariser, David M; Lin, Tina; Martin, Gina; Pillai, Radhakrishnan; Israel, Robert; Ramakrishna, Tage.
Affiliation
  • Gold LS; Henry Ford Hospital, Detroit, Michigan. Electronic address: LSTEIN@hfhs.org.
  • Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sugarman JL; Volunteer Clinical Faculty, University of California, San Francisco, California.
  • Pariser DM; Virginia Clinical Research, Inc, Norfolk, Virginia.
  • Lin T; Ortho Dermatologics, Bridgewater, New Jersey.
  • Martin G; Dow Pharmaceutical Sciences, Inc, a division of Valeant Pharmaceuticals, North America, LLC, Petaluma, California.
  • Pillai R; Dow Pharmaceutical Sciences, Inc, a division of Valeant Pharmaceuticals, North America, LLC, Petaluma, California.
  • Israel R; Valeant Pharmaceuticals, Bridgewater, New Jersey.
  • Ramakrishna T; Valeant Pharmaceuticals, Bridgewater, New Jersey.
J Am Acad Dermatol ; 79(2): 287-293, 2018 Aug.
Article in En | MEDLINE | ID: mdl-29614243
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Clobetasol / Dermatologic Agents / Nicotinic Acids Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2018 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Clobetasol / Dermatologic Agents / Nicotinic Acids Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2018 Type: Article